New flu shot for seniors put to the test
NCT ID NCT07327398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new flu vaccine in 1,200 adults aged 60 and older to see how well it boosts immunity and if it's safe. Participants receive one dose of either the new vaccine or a current one, and researchers check antibody levels and side effects for 30 days. The goal is to find a better way to protect older adults from the flu.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Danjiangkou City Center for Disease Control and Prevention
Wuhan, Hubei, China
-
Yunxi County Center for Disease Control and Prevention
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts